🇺🇸

US SEC Filing Intelligence

· daily

Global High-Priority Regulatory Events — March 13, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus with global insolvency/takeover/regulatory themes), key themes include robust energy project financings and acquisitions contrasting with Indian insolvencies and mixed bank/REIT 10-K results; period-over-period trends show 7/15 10-Ks with revenue growth averaging +20% YoY (e.g., Perfect Corp +14.9%, SenesTech +20%) but 4 with declines averaging -11% (Quest -13.2%), NIM expansions in 3 banks (+14-37 bps), and portfolio expansions in BDCs/lenders. Critical developments feature Venture Global's $8.6B CP2 LNG FID (total $20.7B financing, +100 MTPA capacity), BlackRock's stake increase in Sammaan Capital (+0.06%), and multiple Indian insolvencies (Punj Lloyd, Shree Hanuman). Capital allocation highlights buybacks (CCEP €1B completed, First Northern repurchase program), dividends (5% stock dividend), and financings; insider patterns show institutional buying but key resignations (Greenpanel President, Nine Energy GC). Market implications point to energy export strength amid LNG demand, bank resilience despite deposit shifts, and distress opportunities in India, with catalysts like CoC meetings and IPOs driving near-term volatility.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 13, 2026

The IPO pipeline shows robust activity with 6 S-1 filings on March 13, 2026, dominated by SPACs (2/6), bank mutual-to-stock conversions (2/6), a microcap tech play, and a crypto ETF, highlighting diverse entry points into public markets amid limited traditional IPOs. No broad period-over-period financial trends available due to pre-IPO status, but common $10/share pricing in 4/6 filings signals standardized valuation approach for SPACs and banks versus Dravica's $0.03 outlier. Positive sentiment in CSB Financial contrasts with Dravica's negative going concern flag and JATT II's dilution risks, while neutrals dominate. Bank conversions emphasize depositor/plan priorities for subscription success, SPACs offer dry powder with 24-month windows, and niche plays like crypto staking add volatility. Portfolio implications favor monitoring bank conversions for stable liquidity events and SPACs for M&A catalysts, with cross-filing comparison revealing CSB's $14.55M proceeds potential outperforming Dravica's $120k micro-raise.

6 high priority 6 total filings
· daily

US Earnings Financial Results SEC Filings — March 13, 2026

Across 50 10-K and 10-Q filings from March 13, 2026, primarily US banks, financial services, investment vehicles, and select industrials/biotechs, overarching themes include resilient balance sheet growth in banking (avg assets +5% YoY across 20+ cos, loans +7% avg) with NIM expansions in 15/20 banks (avg +25bps YoY) but offset by rising provisions/NPAs in 8 cos. Non-bank financials and BDCs show strong portfolio ramps (e.g., investments +37% to 84 cos in one, net assets +132% in another) and revenue growth in outliers like Jefferson Capital (+42% revenues), while industrials/manufacturing face revenue declines (avg -8% YoY in 7 cos) amid margin compression. Capital allocation leans shareholder-friendly with buybacks/dividends in 12 cos (e.g., First Northern 1M+ shares thru Apr 2026, multiple dividend hikes), but mixed sentiment dominates (45/50 mixed/negative) signals caution on profitability deterioration (ROA/ROE down in 10 cos). Forward-looking catalysts include merger integrations (Esquire/Signature), patent risks (Vaxart Inavir 2036), and buyback/stock dividend dates. Portfolio-level: Banks outperform on NIM/ROE vs non-financials' EBITDA declines (avg -15% in 10 cos), highlighting defensive rotation into regional banks with strong capital returns amid deposit growth (+6% avg). Critical implication: Opportunities in outperforming banks (e.g., Red River ROE 12.6%) vs risks in provision-heavy lenders.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 13, 2026

Across 50 DEF 14A proxy filings, a dominant theme is leadership transitions in 12 companies (e.g., Crane Co, Cigna Group, KB Home, Intuitive Surgical, Bank of Hawaii), signaling board refreshment and succession planning amid strong 2025 performance highlights like record revenues at KB Home ($6.2B+), Ducommun ($824.7M), and ArcBest ($4.0B). Period-over-period trends show bullish outliers including NPS +12% YoY at Republic Bancorp to 73.4 (2.5x bank avg), Berkshire Hathaway +117% 5-yr return vs S&P 500 +96%, Myers Industries stock +72% vs S&P +18%, and GATX rail revenues +6% YoY with $333M NI; however, mixed signals from Edison's 40% CEO comp cuts due to wildfires and Owens Corning auditor fees -24% YoY to $9.8M. Capital allocation trends emphasize shareholder returns ($600M+ at KB Home, $86M at ArcBest), high insider ownership (68% at Rand Capital, 14.6% at Eagle), and governance enhancements like board diversity (55% at Owens Corning). Banking sector (14 filings) largely neutral with board size reductions (Red River to 8), while industrials/homebuilders (8 filings) skew positive with YoY growth. Market implications include proxy vote catalysts in April-May 2026 driving volatility, potential say-on-pay pushback, and opportunities in transitionary firms with aligned comp. Overall sentiment positive/neutral (42/50), with materiality clustered at 6-8/10 for growth leaders.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 13, 2026

Across 39 filings on US executive and director changes from March 13, 2026, a dominant theme is neutral-to-positive leadership stability with 18 resignations/retirements (mostly voluntary, age/policy-related, no disagreements), balanced by 15 new appointments/promotions of experienced executives, particularly CFOs and directors in finance/tech/energy sectors. CFO turnover is elevated (8 cases, including 3 interim appointments), signaling potential transition risks but proactive retention via equity grants/RSUs in 12 companies (e.g., options/RSUs vesting 2026-2028). Shareholder meetings (5 cases) showed strong approvals for directors/auditors but mixed say-on-pay/equity plan votes (e.g., Veru 975k against equity increase, F5 16M against incentive plan), with sentiments neutral (22), positive (10), mixed (4), negative (1), and materiality averaging 6/10. Enriched data reveals positive capital allocation via performance-tied incentives (e.g., USPH 2026 EBITDA targets $101.6M-$108.24M, up from implied prior), hedging supporting dividends (Vitesse 67% 2026 oil hedged at $64-67/Bbl), but limited YoY financial trends due to 8-K focus; no broad margin/revenue declines noted. Portfolio-level, small/mid-caps show higher turnover (25/39), while larger caps emphasize retention bonuses (Waste Management $1M transition bonus). Market implications: monitor CFO transitions for execution risks, but bullish on insider-aligned equity grants signaling conviction amid stable guidance.

39 high priority 39 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 13, 2026

Across 41 8-K filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive financing maneuvers (e.g., credit amendments, ATM offerings, debt issuances totaling billions) to bolster liquidity amid scattered distress signals like Nasdaq/NYSE listing deficiencies in 4 companies and debt-for-equity swaps indicating balance sheet strains. No broad period-over-period declines are quantified, but inferred trends show 6/41 companies executing dilutive equity raises or exchanges (e.g., NextNRG's $1.75M debt-for-3.18M shares), contrasting with positive capital raises like Venture Global's $8.6B CP2 Phase 2 FID. Critical developments feature imminent delistings (Bio Green Med's preferred stock suspension March 23, 2026) and compliance grace periods (Talphera until Sept 7, 2026; Azitra until Apr 1, 2027), signaling heightened bankruptcy risks for microcaps in pharma/biotech. Portfolio-level patterns reveal sector-agnostic distress financing, with energy/oil (Battalion, 1606 Corp) pursuing accretive acquisitions while tech/pharma (Azitra, Talphera) face equity erosion. Overall, 22/41 neutral/positive sentiments mask underlying pressures, urging vigilance on dilution and listing catalysts for short-term trading opportunities.

41 high priority 41 total filings
· daily

US SEC Trading Suspension Halt Orders — March 13, 2026

Four small-cap companies across healthcare and biotech sectors reported critical US exchange listing compliance failures in March 2026, highlighting a portfolio-level trend of microcap distress with 3/4 filings showing negative sentiment and persistent financial weaknesses like low bid prices, equity deficiencies, and MVPHS shortfalls. No positive YoY/QoQ revenue or margin trends evident; instead, Azitra disclosed net losses across five consecutive fiscal years ended Dec 31, 2025, with stockholders' equity at $3.8M versus $6.0M required, signaling ongoing deterioration from prior $4.0M deficiency. Bio Green Med faces imminent preferred stock delisting and trading suspension on Mar 23, 2026, post-180-day compliance failure from Sep 11, 2025 notice, while Talphera's bid price < $1.00 for 30 days triggers 180-day clock to Sep 7, 2026. Sadot Group resolved a voting rights violation via amendment, marking the sole mixed-positive outcome. Market implications include elevated delisting risks, potential reverse splits, OTC migrations, and short-term price volatility, with no insider buying or dividend hikes to signal conviction—watch for cascading suspensions in weak microcaps.

4 high priority 4 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 13, 2026

Across 39 filings on USA Board Room Changes from March 13, 2026, a dominant theme is elevated C-suite and board turnover, with 12 CFO/EVP Finance-related changes (resignations in Sprout Social, Waste Management, Wheeler REIT; appointments in CONMED, Hexcel, Orgenesis, Mitesco) signaling potential execution risks amid interim leadership in multiple firms. Director resignations/retirements affected 14 companies (e.g., Nine Energy, Vitesse, Six Flags, Goldman Sachs), often voluntary or age-related, balanced by 10 new appointments of experienced executives/directors (e.g., Avidbank, Hexcel CFO from Axcelis, Cyber App Solutions). Equity incentives surged as retention tools, with grants/RSUs/DCAs in 11 firms (Forward Industries options, Adient $500k RSU, Paymentus RSUs, Optimum $9.375M DCAs), reflecting alignment but mixed AGM votes (Veru 975k against equity plan, F5 16.1M against incentives). No broad YoY/QoQ financial declines noted, but Vitesse's 67% 2026 oil production hedged at $64-67/Bbl supports dividends positively; capital allocation leans toward reinvestment via incentives over buybacks/dividends. Portfolio-level pattern: Higher materiality (7-8/10) events cluster in tech/SaaS (Sprout, Asana) and finance (Waste Mgmt, Avidbank), implying sector-specific leadership refreshes for growth/turnarounds. Market implications: Bullish for firms with proven hires, bearish for abrupt exits without successors, creating near-term volatility opportunities.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — March 13, 2026

The 13 filings reveal a surge in SPAC activity with 7/13 involving blank check companies, including 3 IPOs/pricings (Kensington $230M, SUMA $150M) and extensions/deposit (Inception $12k for 1-month to April 13), signaling robust capital raising for M&A amid a 24-36 month combination windows. M&A completions dominate with IF Bancorp merger finalized at $26.40/share cash (delisting March 13), Aditxt's $36M oncology acquisition, and asset sales like Kaanapali's $19.9M land ($10.3M gain) and Moody REIT's $18.85M hotel disposition, though pro forma sales declines noted in 2 cases. Mixed sentiment in 3 filings highlights pro forma deteriorations (New Mountain net assets -3% to $1.153B, realized losses widened to $155M), but overall positive tone in 6/13 with no YoY/QoQ revenue declines beyond isolated pro formas (-$123k 2024 sales for Kaanapali). No insider trading or capital allocation shifts reported across filings, but forward-looking catalysts cluster in March (delistings, trading starts, closings). Portfolio-level trend: Elevated M&A velocity in SPACs/tech/healthcare vs quieter real estate dispositions; implications include heightened takeover premiums and de-SPAC opportunities, with $230M+ trust accounts positioning energy/tech targets.

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 13, 2026

Overnight SEC filings for March 13, 2026, reveal a mix of FY2025 10-K annual reports dominating (e.g., banks, pharma, REITs, BDCs), with period-over-period trends showing resilient revenue growth in select pharma/biotech (avg +25% YoY for Tonix, SenesTech, Vaxart) and banks (Red River net income +25% YoY, First Northern NII +4.8%), but widespread margin pressures and operating losses in industrials/REITs (Quest revenue -13% YoY, BRT NOI flat). Capital allocation leans positive with buybacks (News Corp $1B program, First Northern 1M+ shares authorized), dividends (BRT AFFO +3%), and financings (Karman +$100M revolver, Olenox $810k preferred). Auditor changes (Amplify material weakness) and litigation (Scilex fraud suit) flag risks, while M&A/acquisitions (Battalion 7k acres all-stock) and guidance (Emerald FY26 revenue $490-495M) offer catalysts. Sector themes include banking NIM expansion (Red River +14 bps to 3.38%) vs deposit declines, BDC portfolio ramps (Unknown Co net assets +huge from inception), and mixed pharma commercialization ramps amid high cash burn. Portfolio-level: 12/20 10-Ks mixed sentiment, cash positions strengthened in 8/15 reporting cos (e.g., Tonix to $207M), signaling near-term runway but watch for Q1 2026 guidance shifts. Actionable: Favor banks/BDCs with NIM/ROE gains, avoid litigation-exposed biotech.

35 high priority 15 medium 50 total filings
· daily

DHS Homeland Security Contracts — March 12, 2026

DHS awarded $263.5M in contracts over this period, with all three signaling bullish momentum for border security and infrastructure, including $177M tied to CBP priorities. Leidos shows execution strength with $74M (82%) outlayed on border detection tech, while RQ-AECOM and MARCOM offer full-value upside despite $0 outlay. Cross-cutting firm fixed price structures (two contracts) highlight revenue visibility amid execution risks, prioritizing contractors in hazard detection, construction, and recruitment.

3 total filings
· daily

VA Healthcare & Services Contracts — March 12, 2026

Oracle Health Government Services holds $245M in committed VA EHRM deployment contracts (Waves F&G), non-competitive awards signaling dominant federal health IT position with performance ending April 2026. Zero outlay across both despite 4-5 year terms introduces near-term revenue recognition upside but cash flow timing risks. Bullish backlog supports Oracle's government services growth amid VA modernization.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 12, 2026

Two firm fixed price contracts totaling $178.7M signal strong federal demand for NAICS 236220 commercial building construction, with BL Harbert ($92.5M DOJ dorm renovation) and RQ-AECOM JV ($86.3M DHS Coast Guard rebuild) gaining multi-year revenue through 2026-2028. Significant subcontracting ($29M and $102M respectively) highlights execution dependencies but provides revenue visibility amid full/open competition. Investors in federal construction should overweight bullish signals while monitoring FFP cost risks and outlay progress.

2 total filings
· daily

Federal Professional Services Contracts — March 12, 2026

Miracle Systems LLC, a small disadvantaged business, captured a $224M GSA delivery order for CISA Program Management Support Services under full and open competition, delivering a strong bullish signal with upside to $271M including options. No funds outlayed yet delays revenue but exposes medium-term growth via options and potential extensions through 2026. This sole record highlights SDB competitiveness in federal engineering services amid cybersecurity priorities.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — March 12, 2026

Aggregate $520M in federal IT contracts dominated by Oracle's $245M (47%) VA EHRM deployments, signaling strong healthcare IT modernization demand with bullish revenue visibility into 2026. Booz Allen's $90M FBI win (53% outlayed) adds momentum in justice IT, while GAMA-1 shows NOAA cloud progress (60% outlayed). Options offer $400M+ upside, but zero outlays in three contracts flag near-term cash flow risks.

5 total filings
· daily

New Federal Contractors — March 12, 2026

This $3.98B batch of 14 new federal contracts signals strong bullish momentum for U.S. government contractors, particularly in IT services ($1.1B+ across VA EHRM, CISA, NOAA, FBI, FAA) and construction/remediation ($1.9B including DOE Hanford cleanup and DHS/Coast Guard projects), with 11/14 rated bullish. Oracle Health stands out with $245M in VA EHRM deployments through 2026, while long performance periods (mostly to 2026-2028) provide multi-year revenue visibility despite $0 outlay on 6 contracts signaling delayed cash flows. Neutral signals limited to nonprofits and small private firms limit equity upside there.

14 total filings
· daily

Significant Contract Modifications ($10M+) — March 12, 2026

This $3.98B batch of significant contract modifications signals robust federal spending on IT modernization, border security, environmental cleanup, and healthcare outreach, with 11/14 bullish for key contractors like Oracle ($245M VA EHRM), Leidos ($91M CBP), and Central Plateau Cleanup ($1.7B DOE Hanford). Long performance periods to 2028+ provide multi-year revenue visibility but carry execution risks from zero outlays in 6 contracts and heavy subawarding. Institutional investors should prioritize public firms (Oracle, Leidos, Booz Allen, IBM) for near-term upside from unexercised options totaling >$500M across portfolio.

14 total filings
· daily

Contract Deobligations Alert — March 12, 2026

This $3.98B batch of 14 contract deobligations is dominated by a $1.7B DOE Hanford cleanup award to Central Plateau Cleanup Co., signaling sustained federal remediation spending; IT modernization contracts for Oracle (VA EHRM, $245M combined), Leidos (DHS, $91M), and Booz Allen (DOJ, $90M) highlight multi-year revenue in healthcare and homeland security IT. Eleven bullish signals outweigh 3 neutrals (nonprofits/small biz), with unexercised options exceeding $800M across deals providing upside; however, 6 contracts show $0 outlays despite multi-year histories, flagging execution delays. Investors should prioritize public federal IT/contractors amid 2026-2033 performance tails.

14 total filings
· daily

Contract Option Exercises — March 12, 2026

Contract option exercises totaling $3.98B signal strong federal spending continuity, dominated by $1.7B DOE Hanford cleanup (Central Plateau) and $817M HHS health exchange outreach (IPG Dxtra), with 11/14 bullish on IT services and construction firms. Multi-year commitments through 2028+ provide revenue visibility for public players like Oracle ($245M VA EHRM), Leidos ($91M DHS), and Booz Allen ($90M DOJ IT), amid zero-outlay delays in 6 contracts. Risks from FFP overruns and T&M audits are offset by $500M+ in unexercised options across deals.

14 total filings
· daily

All HHS Contracts — March 12, 2026

A single massive $817M HHS delivery order to IPG DXTRA, INC. highlights robust federal demand for health insurance exchange outreach via advertising, with $770M already outlayed providing immediate revenue visibility through 2027. This Time & Materials contract under full competition signals strength in government comms services, though long duration exposes to fiscal risks. Investors gain a high-confidence bullish entry on IPG DXTRA and NAICS 541810 peers amid concentrated HHS spending.

1 total filings